• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Two cases of dermatomyositis associated with neuroendocrine tumors
AbstractDermatomyositis is an idiopathic inflammatory myopathy with cutaneous manifestations, which is associated with several types of malignancies, yet it has been rarely linked to neuroendocrine tumors (NETs). Here we report two cases of dermatomyositis associated with NETs of differing primary sites. Case 1: A 46-year-old female presented with a facial rash and proximal muscle weakness of both extremities. Investigations revealed elevated creatine kinase (CK) and positive anti-transcriptional intermediary factor 1- γ antibody (TIF1γ). The patient had been diagnosed with dermatomyositis and underwent a total body CT s...
Source: International Cancer Conference Journal - August 31, 2023 Category: Cancer & Oncology Source Type: research

Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti ‐transcriptional intermediary factor 1‐γ antibody‐positive dermatomyositis: A case report
Autoimmune diseases (ADs) such as dermatomyositis (DM) are closely related to cancers. Although there are concerns that immune checkpoint inhibitors (ICIs) may cause immune-related adverse events or exacerbate ADs, clinicians should consider ICIs for SCLC patients with DM because the treatment of malignancy by ICIs improves the symptoms of paraneoplastic AD. AbstractAutoimmune diseases (ADs) are closely related to cancers; 30% of dermatomyositis (DM) cases are associated with malignancy. In lung cancer patients accompanied by DM, the most frequent cancer type is small cell lung cancer (SCLC). Anti-transcriptional intermedi...
Source: Thoracic Cancer - August 19, 2022 Category: Cancer & Oncology Authors: Yoonjoo Kim, Dongil Park, Song ‐Yi Choi, Chaeuk Chung Tags: CASE REPORT Source Type: research

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
Discussion and conclusion. Similar cases in literature are commonly referred to a first-line surgery and the role of neoadjuvant chemotherapy is debatable.PMID:34073827 | PMC:PMC8161769 | DOI:10.3390/curroncol28030182
Source: Current Oncology - June 2, 2021 Category: Cancer & Oncology Authors: Marta Piras Martina Panebianco Matteo Garibaldi Michela Roberto Gioia Merlonghi Patrizia Pellegrini Paolo Marchetti Source Type: research

Pages: 1  2